

Global Genetic Testing for Cancer Risk Market Research Report 2024, Forecast to 2032

<https://marketpublishers.com/r/GE3D85DA2838EN.html>

Date: October 2024

Pages: 149

Price: US\$ 3,200.00 (Single User License)

ID: GE3D85DA2838EN

Abstracts

Report Overview

Cancer risk genetic testing looks for changes in someone's genes. Genetic changes can cause some cancers. Some cancers can run in families.

The global Genetic Testing for Cancer Risk market size was estimated at USD 4631 million in 2023 and is projected to reach USD 13155.05 million by 2032, exhibiting a CAGR of 12.30% during the forecast period.

North America Genetic Testing for Cancer Risk market size was estimated at USD 1474.56 million in 2023, at a CAGR of 10.54% during the forecast period of 2024 through 2032.

This report provides a deep insight into the global Genetic Testing for Cancer Risk market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Genetic Testing for Cancer Risk Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors

and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Genetic Testing for Cancer Risk market in any manner.

Global Genetic Testing for Cancer Risk Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Myriad Genetics

Inc.

Invitae Corporation

Illumina

Inc.

Natera

Inc.

Laboratory Corporation of America Holdings

F. Hoffmann-La Roche Ltd

Quest Diagnostics Incorporated

CooperSurgical

Inc.

Agilent Technologies

Inc.

Thermo Fisher Scientific

Inc.

Twist Bioscience

Sophia Genetics

Fulgent Genetic

Inc.

Medgenome

CENTOGENE

CeGaT

LifeLabs Genetics

Ambry Genetics

BGI

SOFIVA GENOMICS

Yikon Medical

Market Segmentation (by Type)

Breast Cancer Risk Genetic Testing

Stomach Cancer Risk Gene Testing

Rectal Cancer Risk Genetic Testing

Others

Market Segmentation (by Application)

Hospital

Clinic

Laboratory

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Genetic Testing for Cancer Risk Market

Overview of the regional outlook of the Genetic Testing for Cancer Risk Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Genetic Testing for Cancer Risk Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and

restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Genetic Testing for Cancer Risk, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Genetic Testing for Cancer Risk

1.2 Key Market Segments

1.2.1 Genetic Testing for Cancer Risk Segment by Type

1.2.2 Genetic Testing for Cancer Risk Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 GENETIC TESTING FOR CANCER RISK MARKET OVERVIEW

2.1 Global Market Overview

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 GENETIC TESTING FOR CANCER RISK MARKET COMPETITIVE LANDSCAPE

3.1 Global Genetic Testing for Cancer Risk Revenue Market Share by Company (2019-2024)

3.2 Genetic Testing for Cancer Risk Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Company Genetic Testing for Cancer Risk Market Size Sites, Area Served, Product Type

3.4 Genetic Testing for Cancer Risk Market Competitive Situation and Trends

3.4.1 Genetic Testing for Cancer Risk Market Concentration Rate

3.4.2 Global 5 and 10 Largest Genetic Testing for Cancer Risk Players Market Share by Revenue

3.4.3 Mergers & Acquisitions, Expansion

4 GENETIC TESTING FOR CANCER RISK VALUE CHAIN ANALYSIS

4.1 Genetic Testing for Cancer Risk Value Chain Analysis

4.2 Midstream Market Analysis

4.3 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF GENETIC TESTING FOR CANCER RISK MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 Mergers & Acquisitions

5.5.2 Expansions

5.5.3 Collaboration/Supply Contracts

5.6 Industry Policies

6 GENETIC TESTING FOR CANCER RISK MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Genetic Testing for Cancer Risk Market Size Market Share by Type (2019-2024)

6.3 Global Genetic Testing for Cancer Risk Market Size Growth Rate by Type (2019-2024)

7 GENETIC TESTING FOR CANCER RISK MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Genetic Testing for Cancer Risk Market Size (M USD) by Application (2019-2024)

7.3 Global Genetic Testing for Cancer Risk Market Size Growth Rate by Application (2019-2024)

8 GENETIC TESTING FOR CANCER RISK MARKET SEGMENTATION BY REGION

8.1 Global Genetic Testing for Cancer Risk Market Size by Region

8.1.1 Global Genetic Testing for Cancer Risk Market Size by Region

8.1.2 Global Genetic Testing for Cancer Risk Market Size Market Share by Region

8.2 North America

8.2.1 North America Genetic Testing for Cancer Risk Market Size by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe Genetic Testing for Cancer Risk Market Size by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

8.4 Asia Pacific

8.4.1 Asia Pacific Genetic Testing for Cancer Risk Market Size by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

8.5 South America

8.5.1 South America Genetic Testing for Cancer Risk Market Size by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Genetic Testing for Cancer Risk Market Size by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 KEY COMPANIES PROFILE

9.1 Myriad Genetics

9.1.1 Myriad Genetics Genetic Testing for Cancer Risk Basic Information

9.1.2 Myriad Genetics Genetic Testing for Cancer Risk Product Overview

9.1.3 Myriad Genetics Genetic Testing for Cancer Risk Product Market Performance

9.1.4 Myriad Genetics Genetic Testing for Cancer Risk SWOT Analysis

9.1.5 Myriad Genetics Business Overview

9.1.6 Myriad Genetics Recent Developments

9.2 Inc.

- 9.2.1 Inc. Genetic Testing for Cancer Risk Basic Information
- 9.2.2 Inc. Genetic Testing for Cancer Risk Product Overview
- 9.2.3 Inc. Genetic Testing for Cancer Risk Product Market Performance
- 9.2.4 Inc. Genetic Testing for Cancer Risk SWOT Analysis
- 9.2.5 Inc. Business Overview
- 9.2.6 Inc. Recent Developments

9.3 Invitae Corporation

- 9.3.1 Invitae Corporation Genetic Testing for Cancer Risk Basic Information
- 9.3.2 Invitae Corporation Genetic Testing for Cancer Risk Product Overview
- 9.3.3 Invitae Corporation Genetic Testing for Cancer Risk Product Market Performance
- 9.3.4 Invitae Corporation Genetic Testing for Cancer Risk SWOT Analysis
- 9.3.5 Invitae Corporation Business Overview
- 9.3.6 Invitae Corporation Recent Developments

9.4 Illumina

- 9.4.1 Illumina Genetic Testing for Cancer Risk Basic Information
- 9.4.2 Illumina Genetic Testing for Cancer Risk Product Overview
- 9.4.3 Illumina Genetic Testing for Cancer Risk Product Market Performance
- 9.4.4 Illumina Business Overview
- 9.4.5 Illumina Recent Developments

9.5 Inc.

- 9.5.1 Inc. Genetic Testing for Cancer Risk Basic Information
- 9.5.2 Inc. Genetic Testing for Cancer Risk Product Overview
- 9.5.3 Inc. Genetic Testing for Cancer Risk Product Market Performance
- 9.5.4 Inc. Business Overview
- 9.5.5 Inc. Recent Developments

9.6 Natera

- 9.6.1 Natera Genetic Testing for Cancer Risk Basic Information
- 9.6.2 Natera Genetic Testing for Cancer Risk Product Overview
- 9.6.3 Natera Genetic Testing for Cancer Risk Product Market Performance
- 9.6.4 Natera Business Overview
- 9.6.5 Natera Recent Developments

9.7 Inc.

- 9.7.1 Inc. Genetic Testing for Cancer Risk Basic Information
- 9.7.2 Inc. Genetic Testing for Cancer Risk Product Overview
- 9.7.3 Inc. Genetic Testing for Cancer Risk Product Market Performance
- 9.7.4 Inc. Business Overview
- 9.7.5 Inc. Recent Developments

9.8 Laboratory Corporation of America Holdings

9.8.1 Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Basic Information

9.8.2 Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Product Overview

9.8.3 Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Product Market Performance

9.8.4 Laboratory Corporation of America Holdings Business Overview

9.8.5 Laboratory Corporation of America Holdings Recent Developments

9.9 F. Hoffmann-La Roche Ltd

9.9.1 F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Basic Information

9.9.2 F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Product Overview

9.9.3 F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Product Market Performance

9.9.4 F. Hoffmann-La Roche Ltd Business Overview

9.9.5 F. Hoffmann-La Roche Ltd Recent Developments

9.10 Quest Diagnostics Incorporated

9.10.1 Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Basic Information

9.10.2 Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Product Overview

9.10.3 Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Product Market Performance

9.10.4 Quest Diagnostics Incorporated Business Overview

9.10.5 Quest Diagnostics Incorporated Recent Developments

9.11 CooperSurgical

9.11.1 CooperSurgical Genetic Testing for Cancer Risk Basic Information

9.11.2 CooperSurgical Genetic Testing for Cancer Risk Product Overview

9.11.3 CooperSurgical Genetic Testing for Cancer Risk Product Market Performance

9.11.4 CooperSurgical Business Overview

9.11.5 CooperSurgical Recent Developments

9.12 Inc.

9.12.1 Inc. Genetic Testing for Cancer Risk Basic Information

9.12.2 Inc. Genetic Testing for Cancer Risk Product Overview

9.12.3 Inc. Genetic Testing for Cancer Risk Product Market Performance

9.12.4 Inc. Business Overview

9.12.5 Inc. Recent Developments

9.13 Agilent Technologies

9.13.1 Agilent Technologies Genetic Testing for Cancer Risk Basic Information

- 9.13.2 Agilent Technologies Genetic Testing for Cancer Risk Product Overview
- 9.13.3 Agilent Technologies Genetic Testing for Cancer Risk Product Market Performance
- 9.13.4 Agilent Technologies Business Overview
- 9.13.5 Agilent Technologies Recent Developments
- 9.14 Inc.
 - 9.14.1 Inc. Genetic Testing for Cancer Risk Basic Information
 - 9.14.2 Inc. Genetic Testing for Cancer Risk Product Overview
 - 9.14.3 Inc. Genetic Testing for Cancer Risk Product Market Performance
 - 9.14.4 Inc. Business Overview
 - 9.14.5 Inc. Recent Developments
- 9.15 Thermo Fisher Scientific
 - 9.15.1 Thermo Fisher Scientific Genetic Testing for Cancer Risk Basic Information
 - 9.15.2 Thermo Fisher Scientific Genetic Testing for Cancer Risk Product Overview
 - 9.15.3 Thermo Fisher Scientific Genetic Testing for Cancer Risk Product Market Performance
- 9.15.4 Thermo Fisher Scientific Business Overview
- 9.15.5 Thermo Fisher Scientific Recent Developments
- 9.16 Inc.
 - 9.16.1 Inc. Genetic Testing for Cancer Risk Basic Information
 - 9.16.2 Inc. Genetic Testing for Cancer Risk Product Overview
 - 9.16.3 Inc. Genetic Testing for Cancer Risk Product Market Performance
 - 9.16.4 Inc. Business Overview
 - 9.16.5 Inc. Recent Developments
- 9.17 Twist Bioscience
 - 9.17.1 Twist Bioscience Genetic Testing for Cancer Risk Basic Information
 - 9.17.2 Twist Bioscience Genetic Testing for Cancer Risk Product Overview
 - 9.17.3 Twist Bioscience Genetic Testing for Cancer Risk Product Market Performance
 - 9.17.4 Twist Bioscience Business Overview
 - 9.17.5 Twist Bioscience Recent Developments
- 9.18 Sophia Genetics
 - 9.18.1 Sophia Genetics Genetic Testing for Cancer Risk Basic Information
 - 9.18.2 Sophia Genetics Genetic Testing for Cancer Risk Product Overview
 - 9.18.3 Sophia Genetics Genetic Testing for Cancer Risk Product Market Performance
 - 9.18.4 Sophia Genetics Business Overview
 - 9.18.5 Sophia Genetics Recent Developments
- 9.19 Fulgent Genetic
 - 9.19.1 Fulgent Genetic Genetic Testing for Cancer Risk Basic Information
 - 9.19.2 Fulgent Genetic Genetic Testing for Cancer Risk Product Overview

9.19.3 Fulgent Genetic Genetic Testing for Cancer Risk Product Market Performance

9.19.4 Fulgent Genetic Business Overview

9.19.5 Fulgent Genetic Recent Developments

9.20 Inc.

9.20.1 Inc. Genetic Testing for Cancer Risk Basic Information

9.20.2 Inc. Genetic Testing for Cancer Risk Product Overview

9.20.3 Inc. Genetic Testing for Cancer Risk Product Market Performance

9.20.4 Inc. Business Overview

9.20.5 Inc. Recent Developments

9.21 Medgenome

9.21.1 Medgenome Genetic Testing for Cancer Risk Basic Information

9.21.2 Medgenome Genetic Testing for Cancer Risk Product Overview

9.21.3 Medgenome Genetic Testing for Cancer Risk Product Market Performance

9.21.4 Medgenome Business Overview

9.21.5 Medgenome Recent Developments

9.22 CENTOGENE

9.22.1 CENTOGENE Genetic Testing for Cancer Risk Basic Information

9.22.2 CENTOGENE Genetic Testing for Cancer Risk Product Overview

9.22.3 CENTOGENE Genetic Testing for Cancer Risk Product Market Performance

9.22.4 CENTOGENE Business Overview

9.22.5 CENTOGENE Recent Developments

9.23 CeGaT

9.23.1 CeGaT Genetic Testing for Cancer Risk Basic Information

9.23.2 CeGaT Genetic Testing for Cancer Risk Product Overview

9.23.3 CeGaT Genetic Testing for Cancer Risk Product Market Performance

9.23.4 CeGaT Business Overview

9.23.5 CeGaT Recent Developments

9.24 LifeLabs Genetics

9.24.1 LifeLabs Genetics Genetic Testing for Cancer Risk Basic Information

9.24.2 LifeLabs Genetics Genetic Testing for Cancer Risk Product Overview

9.24.3 LifeLabs Genetics Genetic Testing for Cancer Risk Product Market

Performance

9.24.4 LifeLabs Genetics Business Overview

9.24.5 LifeLabs Genetics Recent Developments

9.25 Ambry Genetics

9.25.1 Ambry Genetics Genetic Testing for Cancer Risk Basic Information

9.25.2 Ambry Genetics Genetic Testing for Cancer Risk Product Overview

9.25.3 Ambry Genetics Genetic Testing for Cancer Risk Product Market Performance

9.25.4 Ambry Genetics Business Overview

9.25.5 Ambry Genetics Recent Developments

9.26 BGI

9.26.1 BGI Genetic Testing for Cancer Risk Basic Information

9.26.2 BGI Genetic Testing for Cancer Risk Product Overview

9.26.3 BGI Genetic Testing for Cancer Risk Product Market Performance

9.26.4 BGI Business Overview

9.26.5 BGI Recent Developments

9.27 SOFIVA GENOMICS

9.27.1 SOFIVA GENOMICS Genetic Testing for Cancer Risk Basic Information

9.27.2 SOFIVA GENOMICS Genetic Testing for Cancer Risk Product Overview

9.27.3 SOFIVA GENOMICS Genetic Testing for Cancer Risk Product Market

Performance

9.27.4 SOFIVA GENOMICS Business Overview

9.27.5 SOFIVA GENOMICS Recent Developments

9.28 Yikon Medical

9.28.1 Yikon Medical Genetic Testing for Cancer Risk Basic Information

9.28.2 Yikon Medical Genetic Testing for Cancer Risk Product Overview

9.28.3 Yikon Medical Genetic Testing for Cancer Risk Product Market Performance

9.28.4 Yikon Medical Business Overview

9.28.5 Yikon Medical Recent Developments

10 GENETIC TESTING FOR CANCER RISK REGIONAL MARKET FORECAST

10.1 Global Genetic Testing for Cancer Risk Market Size Forecast

10.2 Global Genetic Testing for Cancer Risk Market Forecast by Region

10.2.1 North America Market Size Forecast by Country

10.2.2 Europe Genetic Testing for Cancer Risk Market Size Forecast by Country

10.2.3 Asia Pacific Genetic Testing for Cancer Risk Market Size Forecast by Region

10.2.4 South America Genetic Testing for Cancer Risk Market Size Forecast by Country

10.2.5 Middle East and Africa Forecasted Consumption of Genetic Testing for Cancer Risk by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)

11.1 Global Genetic Testing for Cancer Risk Market Forecast by Type (2025-2032)

11.2 Global Genetic Testing for Cancer Risk Market Forecast by Application (2025-2032)

12 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Genetic Testing for Cancer Risk Market Size Comparison by Region (M USD)

Table 5. Global Genetic Testing for Cancer Risk Revenue (M USD) by Company
(2019-2024)

Table 6. Global Genetic Testing for Cancer Risk Revenue Share by Company
(2019-2024)

Table 7. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genetic Testing for Cancer Risk as of 2022)

Table 8. Company Genetic Testing for Cancer Risk Market Size Sites and Area Served

Table 9. Company Genetic Testing for Cancer Risk Product Type

Table 10. Global Genetic Testing for Cancer Risk Company Market Concentration Ratio
(CR5 and HHI)

Table 11. Mergers & Acquisitions, Expansion Plans

Table 12. Value Chain Map of Genetic Testing for Cancer Risk

Table 13. Midstream Market Analysis

Table 14. Downstream Customer Analysis

Table 15. Key Development Trends

Table 16. Driving Factors

Table 17. Genetic Testing for Cancer Risk Market Challenges

Table 18. Global Genetic Testing for Cancer Risk Market Size by Type (M USD)

Table 19. Global Genetic Testing for Cancer Risk Market Size (M USD) by Type
(2019-2024)

Table 20. Global Genetic Testing for Cancer Risk Market Size Share by Type
(2019-2024)

Table 21. Global Genetic Testing for Cancer Risk Market Size Growth Rate by Type
(2019-2024)

Table 22. Global Genetic Testing for Cancer Risk Market Size by Application

Table 23. Global Genetic Testing for Cancer Risk Market Size by Application
(2019-2024) & (M USD)

Table 24. Global Genetic Testing for Cancer Risk Market Share by Application
(2019-2024)

Table 25. Global Genetic Testing for Cancer Risk Market Size Growth Rate by
Application (2019-2024)

Table 26. Global Genetic Testing for Cancer Risk Market Size by Region (2019-2024) & (M USD)

Table 27. Global Genetic Testing for Cancer Risk Market Size Market Share by Region (2019-2024)

Table 28. North America Genetic Testing for Cancer Risk Market Size by Country (2019-2024) & (M USD)

Table 29. Europe Genetic Testing for Cancer Risk Market Size by Country (2019-2024) & (M USD)

Table 30. Asia Pacific Genetic Testing for Cancer Risk Market Size by Region (2019-2024) & (M USD)

Table 31. South America Genetic Testing for Cancer Risk Market Size by Country (2019-2024) & (M USD)

Table 32. Middle East and Africa Genetic Testing for Cancer Risk Market Size by Region (2019-2024) & (M USD)

Table 33. Myriad Genetics Genetic Testing for Cancer Risk Basic Information

Table 34. Myriad Genetics Genetic Testing for Cancer Risk Product Overview

Table 35. Myriad Genetics Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 36. Myriad Genetics Genetic Testing for Cancer Risk SWOT Analysis

Table 37. Myriad Genetics Business Overview

Table 38. Myriad Genetics Recent Developments

Table 39. Inc. Genetic Testing for Cancer Risk Basic Information

Table 40. Inc. Genetic Testing for Cancer Risk Product Overview

Table 41. Inc. Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 42. Inc. Genetic Testing for Cancer Risk SWOT Analysis

Table 43. Inc. Business Overview

Table 44. Inc. Recent Developments

Table 45. Invitae Corporation Genetic Testing for Cancer Risk Basic Information

Table 46. Invitae Corporation Genetic Testing for Cancer Risk Product Overview

Table 47. Invitae Corporation Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 48. Invitae Corporation Genetic Testing for Cancer Risk SWOT Analysis

Table 49. Invitae Corporation Business Overview

Table 50. Invitae Corporation Recent Developments

Table 51. Illumina Genetic Testing for Cancer Risk Basic Information

Table 52. Illumina Genetic Testing for Cancer Risk Product Overview

Table 53. Illumina Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 54. Illumina Business Overview

Table 55. Illumina Recent Developments

Table 56. Inc. Genetic Testing for Cancer Risk Basic Information

Table 57. Inc. Genetic Testing for Cancer Risk Product Overview

Table 58. Inc. Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 59. Inc. Business Overview

Table 60. Inc. Recent Developments

Table 61. Natera Genetic Testing for Cancer Risk Basic Information

Table 62. Natera Genetic Testing for Cancer Risk Product Overview

Table 63. Natera Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 64. Natera Business Overview

Table 65. Natera Recent Developments

Table 66. Inc. Genetic Testing for Cancer Risk Basic Information

Table 67. Inc. Genetic Testing for Cancer Risk Product Overview

Table 68. Inc. Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 69. Inc. Business Overview

Table 70. Inc. Recent Developments

Table 71. Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Basic Information

Table 72. Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Product Overview

Table 73. Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 74. Laboratory Corporation of America Holdings Business Overview

Table 75. Laboratory Corporation of America Holdings Recent Developments

Table 76. F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Basic Information

Table 77. F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Product Overview

Table 78. F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 79. F. Hoffmann-La Roche Ltd Business Overview

Table 80. F. Hoffmann-La Roche Ltd Recent Developments

Table 81. Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Basic Information

Table 82. Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Product Overview

Table 83. Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Revenue (M

USD) and Gross Margin (2019-2024)

Table 84. Quest Diagnostics Incorporated Business Overview

Table 85. Quest Diagnostics Incorporated Recent Developments

Table 86. CooperSurgical Genetic Testing for Cancer Risk Basic Information

Table 87. CooperSurgical Genetic Testing for Cancer Risk Product Overview

Table 88. CooperSurgical Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 89. CooperSurgical Business Overview

Table 90. CooperSurgical Recent Developments

Table 91. Inc. Genetic Testing for Cancer Risk Basic Information

Table 92. Inc. Genetic Testing for Cancer Risk Product Overview

Table 93. Inc. Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 94. Inc. Business Overview

Table 95. Inc. Recent Developments

Table 96. Agilent Technologies Genetic Testing for Cancer Risk Basic Information

Table 97. Agilent Technologies Genetic Testing for Cancer Risk Product Overview

Table 98. Agilent Technologies Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 99. Agilent Technologies Business Overview

Table 100. Agilent Technologies Recent Developments

Table 101. Inc. Genetic Testing for Cancer Risk Basic Information

Table 102. Inc. Genetic Testing for Cancer Risk Product Overview

Table 103. Inc. Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 104. Inc. Business Overview

Table 105. Inc. Recent Developments

Table 106. Thermo Fisher Scientific Genetic Testing for Cancer Risk Basic Information

Table 107. Thermo Fisher Scientific Genetic Testing for Cancer Risk Product Overview

Table 108. Thermo Fisher Scientific Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 109. Thermo Fisher Scientific Business Overview

Table 110. Thermo Fisher Scientific Recent Developments

Table 111. Inc. Genetic Testing for Cancer Risk Basic Information

Table 112. Inc. Genetic Testing for Cancer Risk Product Overview

Table 113. Inc. Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 114. Inc. Business Overview

Table 115. Inc. Recent Developments

Table 116. Twist Bioscience Genetic Testing for Cancer Risk Basic Information

Table 117. Twist Bioscience Genetic Testing for Cancer Risk Product Overview

Table 118. Twist Bioscience Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 119. Twist Bioscience Business Overview

Table 120. Twist Bioscience Recent Developments

Table 121. Sophia Genetics Genetic Testing for Cancer Risk Basic Information

Table 122. Sophia Genetics Genetic Testing for Cancer Risk Product Overview

Table 123. Sophia Genetics Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 124. Sophia Genetics Business Overview

Table 125. Sophia Genetics Recent Developments

Table 126. Fulgent Genetic Genetic Testing for Cancer Risk Basic Information

Table 127. Fulgent Genetic Genetic Testing for Cancer Risk Product Overview

Table 128. Fulgent Genetic Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 129. Fulgent Genetic Business Overview

Table 130. Fulgent Genetic Recent Developments

Table 131. Inc. Genetic Testing for Cancer Risk Basic Information

Table 132. Inc. Genetic Testing for Cancer Risk Product Overview

Table 133. Inc. Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 134. Inc. Business Overview

Table 135. Inc. Recent Developments

Table 136. Medgenome Genetic Testing for Cancer Risk Basic Information

Table 137. Medgenome Genetic Testing for Cancer Risk Product Overview

Table 138. Medgenome Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 139. Medgenome Business Overview

Table 140. Medgenome Recent Developments

Table 141. CENTOGENE Genetic Testing for Cancer Risk Basic Information

Table 142. CENTOGENE Genetic Testing for Cancer Risk Product Overview

Table 143. CENTOGENE Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 144. CENTOGENE Business Overview

Table 145. CENTOGENE Recent Developments

Table 146. CeGaT Genetic Testing for Cancer Risk Basic Information

Table 147. CeGaT Genetic Testing for Cancer Risk Product Overview

Table 148. CeGaT Genetic Testing for Cancer Risk Revenue (M USD) and Gross

Margin (2019-2024)

Table 149. CeGaT Business Overview

Table 150. CeGaT Recent Developments

Table 151. LifeLabs Genetics Genetic Testing for Cancer Risk Basic Information

Table 152. LifeLabs Genetics Genetic Testing for Cancer Risk Product Overview

Table 153. LifeLabs Genetics Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 154. LifeLabs Genetics Business Overview

Table 155. LifeLabs Genetics Recent Developments

Table 156. Ambry Genetics Genetic Testing for Cancer Risk Basic Information

Table 157. Ambry Genetics Genetic Testing for Cancer Risk Product Overview

Table 158. Ambry Genetics Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 159. Ambry Genetics Business Overview

Table 160. Ambry Genetics Recent Developments

Table 161. BGI Genetic Testing for Cancer Risk Basic Information

Table 162. BGI Genetic Testing for Cancer Risk Product Overview

Table 163. BGI Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 164. BGI Business Overview

Table 165. BGI Recent Developments

Table 166. SOFIVA GENOMICS Genetic Testing for Cancer Risk Basic Information

Table 167. SOFIVA GENOMICS Genetic Testing for Cancer Risk Product Overview

Table 168. SOFIVA GENOMICS Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 169. SOFIVA GENOMICS Business Overview

Table 170. SOFIVA GENOMICS Recent Developments

Table 171. Yikon Medical Genetic Testing for Cancer Risk Basic Information

Table 172. Yikon Medical Genetic Testing for Cancer Risk Product Overview

Table 173. Yikon Medical Genetic Testing for Cancer Risk Revenue (M USD) and Gross Margin (2019-2024)

Table 174. Yikon Medical Business Overview

Table 175. Yikon Medical Recent Developments

Table 176. Global Genetic Testing for Cancer Risk Market Size Forecast by Region (2025-2032) & (M USD)

Table 177. North America Genetic Testing for Cancer Risk Market Size Forecast by Country (2025-2032) & (M USD)

Table 178. Europe Genetic Testing for Cancer Risk Market Size Forecast by Country (2025-2032) & (M USD)

Table 179. Asia Pacific Genetic Testing for Cancer Risk Market Size Forecast by Region (2025-2032) & (M USD)

Table 180. South America Genetic Testing for Cancer Risk Market Size Forecast by Country (2025-2032) & (M USD)

Table 181. Middle East and Africa Genetic Testing for Cancer Risk Market Size Forecast by Country (2025-2032) & (M USD)

Table 182. Global Genetic Testing for Cancer Risk Market Size Forecast by Type (2025-2032) & (M USD)

Table 183. Global Genetic Testing for Cancer Risk Market Size Forecast by Application (2025-2032) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Industrial Chain of Genetic Testing for Cancer Risk

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Genetic Testing for Cancer Risk Market Size (M USD), 2019-2032

Figure 5. Global Genetic Testing for Cancer Risk Market Size (M USD) (2019-2032)

Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 8. Evaluation Matrix of Regional Market Development Potential

Figure 9. Genetic Testing for Cancer Risk Market Size by Country (M USD)

Figure 10. Global Genetic Testing for Cancer Risk Revenue Share by Company in 2023

Figure 11. Genetic Testing for Cancer Risk Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 12. The Global 5 and 10 Largest Players: Market Share by Genetic Testing for Cancer Risk Revenue in 2023

Figure 13. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 14. Global Genetic Testing for Cancer Risk Market Share by Type

Figure 15. Market Size Share of Genetic Testing for Cancer Risk by Type (2019-2024)

Figure 16. Market Size Market Share of Genetic Testing for Cancer Risk by Type in 2022

Figure 17. Global Genetic Testing for Cancer Risk Market Size Growth Rate by Type (2019-2024)

Figure 18. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 19. Global Genetic Testing for Cancer Risk Market Share by Application

Figure 20. Global Genetic Testing for Cancer Risk Market Share by Application (2019-2024)

Figure 21. Global Genetic Testing for Cancer Risk Market Share by Application in 2022

Figure 22. Global Genetic Testing for Cancer Risk Market Size Growth Rate by Application (2019-2024)

Figure 23. Global Genetic Testing for Cancer Risk Market Size Market Share by Region (2019-2024)

Figure 24. North America Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 25. North America Genetic Testing for Cancer Risk Market Size Market Share by Country in 2023

Figure 26. U.S. Genetic Testing for Cancer Risk Market Size and Growth Rate

(2019-2024) & (M USD)

Figure 27. Canada Genetic Testing for Cancer Risk Market Size (M USD) and Growth Rate (2019-2024)

Figure 28. Mexico Genetic Testing for Cancer Risk Market Size (Units) and Growth Rate (2019-2024)

Figure 29. Europe Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 30. Europe Genetic Testing for Cancer Risk Market Size Market Share by Country in 2023

Figure 31. Germany Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 32. France Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 33. U.K. Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 34. Italy Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 35. Russia Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 36. Asia Pacific Genetic Testing for Cancer Risk Market Size and Growth Rate (M USD)

Figure 37. Asia Pacific Genetic Testing for Cancer Risk Market Size Market Share by Region in 2023

Figure 38. China Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 39. Japan Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 40. South Korea Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 41. India Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 42. Southeast Asia Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 43. South America Genetic Testing for Cancer Risk Market Size and Growth Rate (M USD)

Figure 44. South America Genetic Testing for Cancer Risk Market Size Market Share by Country in 2023

Figure 45. Brazil Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 46. Argentina Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 47. Columbia Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 48. Middle East and Africa Genetic Testing for Cancer Risk Market Size and Growth Rate (M USD)

Figure 49. Middle East and Africa Genetic Testing for Cancer Risk Market Size Market Share by Region in 2023

Figure 50. Saudi Arabia Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 51. UAE Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 52. Egypt Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 53. Nigeria Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 54. South Africa Genetic Testing for Cancer Risk Market Size and Growth Rate (2019-2024) & (M USD)

Figure 55. Global Genetic Testing for Cancer Risk Market Size Forecast by Value (2019-2032) & (M USD)

Figure 56. Global Genetic Testing for Cancer Risk Market Share Forecast by Type (2025-2032)

Figure 57. Global Genetic Testing for Cancer Risk Market Share Forecast by Application (2025-2032)

I would like to order

Product name: Global Genetic Testing for Cancer Risk Market Research Report 2024, Forecast to 2032

Product link: <https://marketpublishers.com/r/GE3D85DA2838EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE3D85DA2838EN.html>